Publicación:
Evaluación del fibrinógeno, Dímero-D y Proteína C Reactiva ultrasensible en la diabetes mellitus tipo 2

Vista sencilla de ítem
dc.contributor.advisorCantero Guevara, Miriam Elena
dc.contributor.advisorGarcía del Castillo, Yuranis Andrea
dc.contributor.authorHerrera Ariza, María José
dc.contributor.authorRamos Barboza, Daniel Arturo
dc.contributor.datamanagerUniversidad de Córdoba
dc.contributor.juryAlvis Ramos, Erasmo Manuel
dc.contributor.juryNoble González, Agustina María
dc.date.accessioned2025-07-23T13:14:21Z
dc.date.available2026-07-23
dc.date.available2025-07-23T13:14:21Z
dc.date.issued2025-07-23
dc.description.abstractObjetivo. Evaluar la concentración de fibrinógeno, dímero-D y Proteína C reactiva ultrasensible (PCR-us) en individuos con diagnóstico de diabetes mellitus tipo 2 (DM2), adscritos a la unidad administrativa del fondo de salud de la Universidad de Córdoba, con el fin de determinar su utilidad como moléculas de riesgo inflamatorio y trombótico. Materiales y métodos. Se realizó un estudio transversal, prospectivo y descriptivo. Se incluyeron treinta (30) individuos distribuidos en dos grupos: 15 individuos con diagnóstico confirmado de DM2 y 15 individuos no diabéticos. La concentración de fibrinógeno se determinó por un inmunoensayo absorbente ligado a enzima. La concentración de PCR-us y dímero-D se evaluó mediante ensayos de inmunoturbidimetría e inmunofluorescencia, respectivamente. Resultados. La mayoría de los individuos con DM2 tenían edades entre los 40 y 50 años, sobrepeso y obesidad. Se observó una mayor concentración de fibrinógeno (Fg) en los pacientes con DM2 en comparación con el grupo control (GC), con diferencias estadísticas significativa entre los dos grupos (p=0,00015). La concentración de Dímero-D y PCR-us en los pacientes con DM2 fue similar al grupo control, aunque los valores tienden a ser más altos en los pacientes con DM2. Conclusiones. La mayoría de los individuos con DM2 de la población de estudio tiene sobrepeso u obesidad y pertenecen a estratos socioeconómicos bajos. La concentración elevada de fibrinógeno en la población con DM2 indican la presencia de inflamación, características de esta patología.spa
dc.description.abstractObjective: This study aimed to evaluate the concentrations of hs-CRP, fibrinogen, and D-dimer in individuals diagnosed with T2DM who are affiliated with the health services of the University of Córdoba, to determine their utility as molecules of inflammatory and thrombotic risk.Materials and methods: A descriptive, prospective cross-sectional study was conducted, including 30 individuals divided into two groups: 15 with confirmed T2DM and 15 non-diabetic controls. Fibrinogen levels were measured using ELISA, while hs-CRP and D-dimer levels were assessed via immunoturbidimetry and immunofluorescence, respectively. Results: Most diabetic participants were between 40 and 50 years old and presented with overweight or obesity. Fibrinogen levels were significantly higher in the diabetic group compared to the control group (p = 0.00015), while hs-CRP and D-dimer levels were slightly elevated but showed no statistically significant difference. Conclusions: The findings suggest that patients with T2DM, particularly those with excess body weight and from lower socioeconomic backgrounds, may exhibit elevated fibrinogen levels, indicating an ongoing inflammatory process characteristic of the disease.eng
dc.description.degreelevelPregrado
dc.description.degreenameBacteriólogo(a)
dc.description.modalityArtículo
dc.description.tableofcontentsIntroducciónspa
dc.description.tableofcontentsObjetivo generalspa
dc.description.tableofcontentsObjetivos específicosspa
dc.description.tableofcontentsMateriales y métodosspa
dc.description.tableofcontentsResultadosspa
dc.description.tableofcontentsDiscusiónspa
dc.description.tableofcontentsConclusionesspa
dc.description.tableofcontentsRecomendacionesspa
dc.description.tableofcontentsAgradecimientosspa
dc.description.tableofcontentsBibliografíaspa
dc.format.mimetypeapplication/pdf
dc.identifier.instnameUniversidad de Córdoba
dc.identifier.reponameRepositorio Universidad de Córdoba
dc.identifier.repourlhttps://repositorio.unicordoba.edu.co
dc.identifier.urihttps://repositorio.unicordoba.edu.co/handle/ucordoba/9460
dc.language.isospa
dc.publisherUniversidad de Córdoba
dc.publisher.facultyFacultad de Ciencias de la Salud
dc.publisher.placeMontería, Córdoba, Colombia
dc.publisher.programBacteriología
dc.relation.referencesOMS. Diabetes. Datos y cifras [Internet]. Who.int. 2024. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/diabetes
dc.relation.referencesDía mundial de la diabetes 2024 [Internet]. Cuenta de Alto Costo - Fondo Colombiano de Cuentas de Alto Costo, organismo técnico no gubernamental del Sistema General de Seguridad Social en Salud de Colombia creado mediante el Decreto 2699 de 2007. Cuenta de Alto Costo; 2024. Disponible en: https://cuentadealtocosto.org/general/dia-mundial-de-la-diabetes/
dc.relation.referencesBorén J, Öörni K, Catapano AL. The link between diabetes and cardiovascular disease. Atherosclerosis [Internet]. 2024;394(117607):117607. Disponible en: http://dx.doi.org/10.1016/j.atherosclerosis.2024.117607
dc.relation.referencesBadawi A. Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention. Diabetes Metab Syndr Obes [Internet]. 2010; 3:173–86. Disponible en: https://www.dovepress.com/type-2-diabetes-mellitus-and-inflammation-prospects-for-biomarkers-of--peer-reviewed-fulltext-article-DMSOTT
dc.relation.referencesFesta A, D’Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS): The Insulin Resistance Atherosclerosis Study (IRAS). Circulation [Internet]. 2000;102(1):42–7. Disponible en: http://dx.doi.org/10.1161/01.cir.102.1.42
dc.relation.referencesMaritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol [Internet]. 2003;17(1):24–38. Disponible en: http://dx.doi.org/10.1002/jbt.10058
dc.relation.referencesDebi H, Itu ZT, Amin MT, Hussain F, Hossain MS. Association of serum C-reactive protein (CRP) and D-dimer concentration on the severity of COVID-19 cases with or without diabetes: a systematic review and meta-analysis. Expert Rev Endocrinol Metab [Internet]. 2022;17(1):83–93. Disponible en: http://dx.doi.org/10.1080/17446651.2022.2002146
dc.relation.referencesYang S, Cai H, Hu Z, Huang W, Fu Q, Xia P, et al. Combination of C-reactive protein and fibrinogen-to-albumin ratio as a novel predictor of all-cause mortality in heart failure patients. Open Med (Warsz) [Internet]. 2024;19(1):20241045. Disponible en: http://dx.doi.org/10.1515/med-2024-1045
dc.relation.referencesRidker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med [Internet]. 2000;342(12):836–43. Disponible en: http://dx.doi.org/10.1056/NEJM200003233421202
dc.relation.referencesPradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA [Internet]. 2001;286(3):327–34. Disponible en: http://dx.doi.org/10.1001/jama.286.3.327
dc.relation.referencesBarzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: The Cardiovascular Health Study. Diabetes [Internet]. 2001;50(10):2384–9. Disponible en: http://dx.doi.org/10.2337/diabetes.50.10.2384
dc.relation.referencesHan TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean MEJ, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care [Internet]. 2002;25(11):2016–21. Disponible en: http://dx.doi.org/10.2337/diacare.25.11.2016
dc.relation.referencesFletcher B, Gulanick M, Lamendola C. Risk factors for type 2 diabetes mellitus. J Cardiovasc Nurs [Internet]. 2002;16(2):17–23. Disponible en: http://dx.doi.org/10.1097/00005082-200201000-00003
dc.relation.referencesVilar R, Fish RJ, Casini A, Neerman-Arbez M. Fibrin(ogen) in human disease: both friend and foe. Haematologica [Internet]. 2020;105(2):284–96. Disponible en: http://dx.doi.org/10.3324/haematol.2019.236901
dc.relation.referencesKafle DR, Shrestha P. Study of fibrinogen in patients with diabetes mellitus. Nepal Med Coll J. 2010;12(1):34–7
dc.relation.referencesAbdelmonem M, Abdulla S, Wasim H, Elawamy H. The correlation between Plasma Fibrinogen Levels and Glycemic Status in type 2 Diabetes Mellitus. Am J Clin Pathol [Internet]. 2023;160(Supplement_1): S19–20. Disponible en: http://dx.doi.org/10.1093/ajcp/aqad150.042
dc.relation.referencesStec JJ, Silbershatz H, Tofler GH, Matheney TH, Sutherland P, Lipinska I, et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation [Internet]. 2000;102(14):1634–8. Disponible en: http://dx.doi.org/10.1161/01.cir.102.14.1634
dc.relation.referencesPop NO, Mohan AG, Zaha DC, Babeș PA. D-dimers, potential predictive factor of survival in acute ischemic stroke in patient with diabetes. Med Interna [Internet]. 2020;17(1):29–34. Disponible en: http://dx.doi.org/10.2478/inmed-2020-0099
dc.relation.referencesBryk AH, Konieczyńska M, Polak M, Plicner D, Bochenek M, Undas A. Plasma fibrin clot properties and cardiovascular mortality in patients with type 2 diabetes: a long-term follow-up study. Cardiovasc Diabetol [Internet]. 2021;20(1):47. Disponible en: http://dx.doi.org/10.1186/s12933-021-01230-9
dc.relation.referencesHashim Ibrahim Elbashir I, Kamal Ali Mohamed H, Adam Essa ME, Seri A. Comparison between D-dimer levels in diabetic and non-diabetic positive COVID-19 adult patients: A hospital-based study. Endocrinol Diabetes Metab [Internet]. 2022;5(4):e349. Disponible en: http://dx.doi.org/10.1002/edm2.349
dc.relation.referencesAmerican Diabetes Association. (2023). Estadísticas sobre la diabetes 2023. Recuperado de: https://diabetes.org/es/sobre-la-diabetes/estadisticas/sobre-la-diabetes
dc.relation.referencesHsu C-C, Lee C-H, Wahlqvist ML, Huang H-L, Chang H-Y, Chen L, et al. Poverty increases type 2 diabetes incidence and inequality of care despite universal health coverage. Diabetes Care [Internet]. 2012;35(11):2286–92. Disponible en: http://dx.doi.org/10.2337/dc11-2052
dc.relation.referencesArteaga JM, Latorre-Santos C, Ibáñez-Pinilla M, Ballesteros-Cabrera MDP, Barón LY, Velosa SA, et al. Prevalence of type 2 diabetes, overweight, obesity, and metabolic syndrome in adults in Bogotá, Colombia, 2022-2023: A cross‑sectional population survey. Ann Glob Health [Internet]. 2024;90(1):67. Disponible en: http://dx.doi.org/10.5334/aogh.4539
dc.relation.referencesHamidullah, Ahmad I, Ashraf, Ali M, Hussain M, Zakirullah. Correlation between plasma fibrinogen levels and microvascular complications in type 2 diabetes. J Pak Med Assoc [Internet]. 2024;74(8):1441–8. Disponible en: http://dx.doi.org/10.47391/JPMA.10403
dc.relation.referencesWang K, Xu W, Zha B, Shi J, Wu G, Ding H. Fibrinogen to albumin ratio as an independent risk factor for type 2 diabetic kidney disease. Diabetes Metab Syndr Obes [Internet]. 2021;14:4557–67. Disponible en: http://dx.doi.org/10.2147/DMSO.S337986
dc.relation.referencesZhuang L, Yu C, Xu F, Zhao L-H, Wang X-H, Wang C-H, et al. Increased plasma D-dimer levels may be a promising indicator for diabetic peripheral neuropathy in type 2 diabetes. Front Endocrinol (Lausanne) [Internet]. 2022;13:930271. Disponible en: http://dx.doi.org/10.3389/fendo.2022.930271
dc.relation.referencesCheng L, Fu Q, Zhou L, Fan Y, Liu F, Fan Y, Zhang X, Lin W, Wu X. D dimer as a predictor of cardiovascular outcomes in patients with diabetes mellitus. BMC Cardiovasc Disord. 2022 Mar 4;22(1):82. doi: 10.1186/s12872-022-02531-x
dc.relation.referencesMishra Y, Pathak BK, Mohakuda SS, Tilak TVSVGK, Sen S, Harikrishnan P, Singh R, Singh AR. Relation of D dimer levels of COVID 19 patients with diabetes mellitus. Diabetes Metab Syndr. 2020 Oct;14(6):1927–1930. doi: 10.1016/j.dsx.2020.09.035.
dc.relation.referencesJiang Y, Yu J. Association between hs-CRP/HDL with type 2 diabetes mellitus in middle-aged and elderly people: a cross-sectional study from CHARLS. Front Endocrinol (Lausanne) [Internet]. 2025;16:1471292. Disponible en: http://dx.doi.org/10.3389/fendo.2025.1471292
dc.relation.referencesKamath S, Prasanna U, Srivastava S, Sunder A. The Study of Relationship between Plasma Fibrinogen Level and the Macrovascular Complications in Type 2 Diabetes Mellitus patients in a Tertiary Health Care Centre in Eastern India [Internet]. Athenaeumpub. 2024. Disponible en: https://athenaeumpub.com/the-study-of-relationship-between-plasma-fibrinogen-level-and-the-macrovascular-complications-in-type-2-diabetes-mellitus-patients-in-a-tertiary-health-care-centre-in-eastern-india-2/
dc.rightsCopyright Universidad de Córdoba, 2025
dc.rights.accessrightsinfo:eu-repo/semantics/embargoedAccess
dc.rights.coarhttp://purl.org/coar/access_right/c_f1cf
dc.rights.licenseAtribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.keywordsDiabeteseng
dc.subject.keywordsFibrinogeneng
dc.subject.keywordsHigh-sensitivity C-reactive proteineng
dc.subject.keywordsD-Dimereng
dc.subject.keywordsInflammationeng
dc.subject.proposalDiabetesspa
dc.subject.proposalFibrinógenospa
dc.subject.proposalDímero-Dspa
dc.subject.proposalProteína C reactiva ultrasensiblespa
dc.subject.proposalInflamaciónspa
dc.titleEvaluación del fibrinógeno, Dímero-D y Proteína C Reactiva ultrasensible en la diabetes mellitus tipo 2spa
dc.typeTrabajo de grado - Pregrado
dc.type.coarhttp://purl.org/coar/resource_type/c_7a1f
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.contentText
dc.type.driverinfo:eu-repo/semantics/bachelorThesis
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dspace.entity.typePublication
Archivos
Bloque original
Mostrando 1 - 2 de 2
No hay miniatura disponible
Nombre:
HerreraArizaMaría José_RamosBarbozaDanielArturo.pdf
Tamaño:
436.67 KB
Formato:
Adobe Portable Document Format
Descargar
No hay miniatura disponible
Nombre:
FormatodeAutorizaciónPublicación.pdf
Tamaño:
1.48 MB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
15.18 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
D.C.F. Articulos